Milind Javle
M.D. Anderson Cancer Center · Roswell Park Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Milind Javle as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:23 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT05948475 · Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in CholangiocarcinomaTransThera Sciences (Nanjing), Inc. · active not recruiting · Cholangiocarcinoma · principal investigator
- Ph2NCT04919642 · Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in CholangiocarcinomaTransThera Sciences (Nanjing), Inc. · completed · Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation · principal investigator
- Ph2NCT03432676 · Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic CancerM.D. Anderson Cancer Center · withdrawn · ATM Gene Mutation, Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation · principal investigator
- Ph2NCT02677038 · Olaparib in Treating Patients With Stage IV Pancreatic CancerM.D. Anderson Cancer Center · completed · Metastatic Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7 · principal investigator
- Ph2NCT02392637 · Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary CancersM.D. Anderson Cancer Center · completed · Stage III Intrahepatic Cholangiocarcinoma AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7, Stage IIIB Gallbladder Cancer AJCC v7 · principal investigator
- Ph1NCT00968604 · C-VISA BikDD: Liposome in Advanced Pancreatic CancerM.D. Anderson Cancer Center · withdrawn · Pancreatic Cancer · study chair
- Ph1/Ph2NCT00769483 · MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic CancerM.D. Anderson Cancer Center · completed · Pancreatic Cancer, Pancreatic Adenocarcinoma · principal investigator
- Ph2NCT00640978 · Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic CancerM.D. Anderson Cancer Center · terminated · Pancreatic Cancer · principal investigator
- Ph1/Ph2NCT00093652 · Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal CancerRoswell Park Cancer Institute · terminated · Esophageal Cancer · principal investigator
- Ph2NCT00084942 · Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the GallbladderRoswell Park Cancer Institute · completed · Extrahepatic Bile Duct Cancer, Gallbladder Cancer · principal investigator
- N/ANCT00040820 · Oxaliplatin in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal CancerRoswell Park Cancer Institute · completed · Colorectal Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:23 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Phase I Study of the BikDD Nanoparticle for Advanced Cancer of the PancreasR21CA135604 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2009 to 2011 · $328,636 awarded in 2011Grant number is on one of their registry trials
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Experimental Medicine ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2013 to 2026Named on NCT03432676
Most cited trial papers
Clinical-trial papers with this author name in pancreatic cancer, ranked by citations from NIH iCite, fetched 2026-11-12 12:23 UTC. The ranking covers the 200 most relevant of 18 PubMed records, and a shared surname and initials can bring in a namesake. All 18 on PubMed
- 243 citationsRCR 5.8
- Transport properties of pancreatic cancer describe gemcitabine delivery and response.J Clin Invest · 2014154 citationsRCR 4.3
- Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.BMC Cancer · 2010152 citationsRCR 3.2
- Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer.Mol Oncol · 2016127 citationsRCR 4.1
- 104 citationsRCR 4.9
- EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study.Gastrointest Endosc · 201297 citationsRCR 2.9
- Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer.J Immunother Cancer · 202087 citationsRCR 3.2
- NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma.Ann Surg Oncol · 202379 citationsRCR 7.8
- A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study.Ann Surg Oncol · 200755 citationsRCR 1.7
- 48 citationsRCR 5.0